WUXI BIOLOGICS UNSP/ADR - WXXWY STOCK NEWS

WuXi Biologics (2269.HK) to expand commercial manufacturing capacity in the U.S., increasing total manufacturing capacity to 36,000 liters, creating 200 new jobs, and aiming for GMP release in 2026.

WuXi Biologics (2269.HK) has been named to the 2023 S&P Dow Jones Sustainability™ World Index (DJSI World) and DJSI Emerging Markets Index, recognized as a sustainability leader by S&P Global. The company was ranked number one in its sector in the Corporate Sustainability Assessment (CSA). WuXi Biologics CEO, Dr. Chris Chen, expressed pride in the achievement, emphasizing the company's commitment to enhancing ESG capabilities and sustainable growth. WuXi Biologics has demonstrated its dedication to sustainability through various ESG achievements, including becoming a signatory to the United Nations Global Compact, receiving an AAA rating from MSCI ESG Ratings, and being awarded the EcoVadis Sustainability Rating's Platinum Medal.

WuXi Biologics (2269.HK) has been awarded the EcoVadis Sustainability Rating's Platinum Medal, ranking in the top 1% of over 100,000 companies evaluated. The company has been recognized for outstanding performance across Environment, Labor & Human Rights, Ethics, and Sustainable Procurement, making it a trusted partner by global clients for its strong sustainability commitment.

WuXi Biologics (2269.HK) has completed its first end-to-end continuous drug substance (DS) manufacturing from perfused cell culture to final UF/DF pool at pilot scale. The company achieved an average daily productivity of 6 g/L/day for a mAb molecule during the 18-day production phase, leading to a significantly high accumulated volumetric productivity at 105 g/L in the 25-day continuous cell culture process. The total yield calculated from Protein A capture to UF/DF reached nearly 80%, delivering over 3 kg protein from 40 L working volume. WuXi Biologics' end-to-end continuous DS manufacturing enabled by WuXiUPTM allows a 1,000 L disposable bioreactor to produce more than 60 kg of mAb per batch and approximately 800 kg per year, achieving productivity comparable to a traditional 10,000-20,000L bioreactor. The company aims to expedite biologics development, reduce the cost of goods (COGS) of commercial products, and increase operational flexibility due to minimal facility footprint utilization.

WuXi Biologics (2269.HK) has received an AAA rating from MSCI ESG Ratings, signaling outstanding performance in key ESG issues like climate change, corporate governance, talent development, and product safety & quality. This recognition solidifies WuXi Biologics' position as an industry leader in managing significant ESG opportunities.

WuXi Biologics launches WuXiUI™, a new proprietary bioprocessing platform that enhances productivity and reduces costs in biologics development and manufacture.

WuXi Biologics congratulates Amicus Therapeutics on FDA approval for Pombiliti™ and Opfolda™ for late-onset Pompe disease. WuXi Biologics is the exclusive manufacturing partner for the therapy.

WuXi Biologics reports solid business performance with sustained growth momentum and strong backlog

WuXi Biologics and Boostimmune have signed a Memorandum of Understanding for research and discovery services. Boostimmune will have access to WuXi Biologics' integrated discovery services and expertise in antibody discovery. WuXi Biologics will be the exclusive service partner to support Boostimmune in generating different modality candidates.